Guizhou Sanli Pharmaceutical Co Ltd is a China-based company primarily engaged in the research, development, production, and sales of pharmaceuticals. The products primarily include respiratory medications, tonics, gynecological medications, orthopedic medications, and cardiovascular medications. The specific pharmaceutical products include Kaihoujian Spray (children's version), Kaihoujian Spray, Qijiao Shengbai Capsules, Fuke Zaizao Pills, Zhike Huatan Pills, Huangqi Granules, and Qiangli Tianma Duzhong Capsules. The Company distributes its products within the domestic market.

Employees

1,887

Sector

Pharmaceuticals

Calendar

Earnings release - Q2 2026

More about the company

Quotes

Date	Price	Change	Volume
17/07/26	CN¥10.95	-4.03%	15,585,800
16/07/26	CN¥11.41	-1.98%	15,682,700
15/07/26	CN¥11.64	+1.66%	13,522,600
14/07/26	CN¥11.45	-0.35%	11,281,400
13/07/26	CN¥11.49	-4.09%	11,715,395

End-of-day quote Shanghai S.E.

More quotes

Income Statement and Estimates

More financial data

Annual profits - Rate of surprise

Company calendar

End-of-day quote Shanghai S.E. Other stock markets 17/07/2026			5-day change	1st Jan Change
10.95 ^CNY	-4.03%		-8.60%	-6.41%

05-26	Guizhou Sanli Pharmaceutical to Raise Up to 700 Million Yuan in Private Placement	MT
05-25	Guizhou Sanli pharmaceutical to raise funds via private placement	RE

Market Cap	4.43B 654M 571M 527M 486M 916M 62.97B 936M 6.3B 2.48B 30.84B 2.46B 2.4B 106B	P/E 2024	19.4x	P/E 2025	106x
Enterprise Value	4.78B 705M 616M 569M 524M 988M 67.92B 1.01B 6.8B 2.67B 33.26B 2.65B 2.59B 115B	EV / Sales 2024	2.48x	EV / Sales 2025	2.99x
Free-Float	41.36%	Yield 2024	2.62%	Yield 2025	0.51%

05-26	Guizhou Sanli Pharmaceutical to Raise Up to 700 Million Yuan in Private Placement	MT
05-25	Guizhou Sanli pharmaceutical to raise funds via private placement	RE
05-24	Guizhou Sanli Pharmaceutical Co.,Ltd announced that it expects to receive CNY 700 million in funding	CI
04-26	Guizhou Sanli Pharmaceutical Co.,Ltd announces Annual dividend, payable on June 30, 2026	CI
04-26	Guizhou Sanli Pharmaceutical Co.,Ltd Reports Earnings Results for the Full Year Ended December 31, 2025	CI
04-26	Guizhou Sanli Pharmaceutical Co.,Ltd Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
04-22	Guizhou Sanli Pharmaceutical Co.,Ltd announced that it expects to receive CNY 300 million in funding	CI
12-03	Sanli Pharma to Withdraw Stake in Associate; Shares Down 3%	MT
27/10/25	Guizhou Sanli Pharmaceutical Co.,Ltd Reports Earnings Results for the Nine Months Ended September 30, 2025	CI
12/09/25	Tranche Update on Guizhou Sanli Pharmaceutical Co.,Ltd's Equity Buyback Plan announced on September 13, 2024.	CI
10/09/25	Guizhou Sanli Pharmaceutical Co.,Ltd's Equity Buyback announced on September 12, 2024, has closed with 7,869,300 shares, representing 1.93% for CNY 99.95 million.	CI
27/08/25	Guizhou Sanli Pharmaceutical Co.,Ltd Reports Earnings Results for the Half Year Ended June 30, 2025	CI
22/04/25	Guizhou Sanli Pharmaceutical Co.,Ltd announces Annual dividend, payable on June 26, 2025	CI

1 day	-4.03%
1 week	-8.60%
Current month	-13.16%
1 month	-27.68%
3 months	-0.27%
6 months	-7.83%
Current year	-6.41%

GuiZhou SanLi Pharmaceutical Co.,Ltd Share Price

Stocks

603439

CNE1000040B4

Pharmaceuticals

Valuation: GuiZhou SanLi Pharmaceutical Co.,Ltd

Chart: GuiZhou SanLi Pharmaceutical Co.,Ltd

Latest news : GuiZhou SanLi Pharmaceutical Co.,Ltd

Quotes and Performance

Course Extremes

Managers and Directors: GuiZhou SanLi Pharmaceutical Co.,Ltd

Latest insider transactions

Other Pharmaceuticals

Financials

Company Profile

Quotes

Income Statement and Estimates

Annual profits - Rate of surprise

1 week	10.85	12.26
1 month	10.85	16.25
Current year	10.49	17.46
1 year	10.49	17.46
3 years	10.49	20.34
5 years	10.49	21.28
10 years	8.82	44.1

Manager	Title	Age	Since
Qian Fan Zhang CEO	Chief Executive Officer	41	26/05/2024
Hai Zhang CEO	Chief Executive Officer	41	31/08/2011
Ke Guo DFI	Director of Finance/CFO	39	31/10/2024

Director	Title	Age	Since
Shi Gui Chen BRD	Director/Board Member	63	11/12/2022
Wei Sheng Feng BRD	Director/Board Member	66	09/10/2024
Hai Zhang CHM	Chairman	41	28/02/2018

Date	Insider	Type	Main position	Quantity	% Market Cap.
11/09/24	Hai Zhang	Sell	Chief Executive Officer	21,000,000	5.1428%
02/08/24	Jue Ben Wang	Buy	Director	13,000	0.0032%
05/08/23	Yuan Yu	Sell		25,000	0.0061%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
GUIZHOU SANLI PHARMACEUTICAL CO.,LTD	-4.03%	-8.60%	-15.96%	-31.99%	654M
ELI LILLY AND COMPANY	+0.85%	-0.80%	+54.84%	+163.70%	1,051B
JOHNSON & JOHNSON	+1.23%	-1.53%	+55.26%	+59.07%	609B
ABBVIE INC.	+0.04%	+2.58%	+32.96%	+88.75%	450B
ROCHE HOLDING AG	+0.78%	-0.71%	+30.04%	+24.61%	330B
NOVARTIS AG	+1.41%	+0.58%	+33.92%	+47.20%	284B
ASTRAZENECA PLC	-0.27%	-1.87%	+22.13%	+23.47%	263B
NOVO NORDISK A/S	-1.76%	+2.37%	-22.19%	-38.45%	223B
AMGEN INC.	-1.42%	+0.80%	+22.81%	+60.77%	198B
GILEAD SCIENCES, INC.	-1.48%	+3.43%	+23.42%	+73.31%	167B
Average	-0.51%	+0.01%	+23.72%	+47.04%	357.57B
Weighted average by Cap.	+0.21%	+0.02%	+37.74%	+81.47%

	2024	2025
Net sales	2.14B 316M 276M 255M 235M 443M 30.47B 453M 3.05B 1.2B 14.92B 1.19B 1.16B 51.37B	1.7B 251M 220M 203M 187M 352M 24.19B 360M 2.42B 952M 11.85B 943M 923M 40.79B
Net income	274M 40.43M 35.33M 32.6M 30.05M 56.64M 3.89B 57.9M 390M 153M 1.91B 152M 148M 6.56B	46.25M 6.82M 5.96M 5.5M 5.07M 9.56M 657M 9.77M 65.77M 25.87M 322M 25.63M 25.07M 1.11B
Net Debt	108M 15.88M 13.88M 12.81M 11.81M 22.25M 1.53B 22.75M 153M 60.22M 749M 59.65M 58.34M 2.58B	349M 51.45M 44.96M 41.49M 38.24M 72.08M 4.95B 73.68M 496M 195M 2.43B 193M 189M 8.35B